Kim Margolin - Researcher Profile | RDL Research Database

Publications

2 shown

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas , Igor Puzanov , Reinhard Dummer +33 more

2015 The Lancet Oncology 1528 citations

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Dirk Schadendorf , F. Stephen Hodi , Caroline Robert +7 more

Purpose To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma, we performed a pooled analysis of overall survi...

2015 Journal of Clinical Oncology 2068 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 3,596
Institution: Seattle Cancer Care Alliance

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-5248-4356

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.